{"id":"bucy-vs-buflu","safety":{"commonSideEffects":[{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatic veno-occlusive disease"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Graft-versus-host disease"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BuCy (busulfan-cyclophosphamide) and BuFlu (busulfan-fludarabine) are myeloablative or reduced-intensity conditioning regimens used prior to allogeneic hematopoietic stem cell transplantation. Busulfan is an alkylating agent that damages DNA and destroys bone marrow cells, while cyclophosphamide or fludarabine provide additional immunosuppression and cytotoxic effects. These regimens eliminate residual disease and create space for donor stem cell engraftment.","oneSentence":"BuCy and BuFlu are conditioning regimens that use chemotherapy agents (busulfan combined with either cyclophosphamide or fludarabine) to prepare patients for hematopoietic stem cell transplantation by suppressing bone marrow and the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:06.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies"},{"name":"Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT00774280","phase":"PHASE3","title":"Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2002-05","conditions":"Leukemia, Myelodysplastic Syndrome","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["busulfan plus cyclophosphamide versus fludarabine"],"phase":"phase_3","status":"active","brandName":"BuCy vs BuFlu","genericName":"BuCy vs BuFlu","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BuCy and BuFlu are conditioning regimens that use chemotherapy agents (busulfan combined with either cyclophosphamide or fludarabine) to prepare patients for hematopoietic stem cell transplantation by suppressing bone marrow and the immune system. Used for Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}